Dale Sander Biography and Net Worth

CFO of Humacyte

Mr. Sander has served as Chief Financial Officer of six other life science companies during both private and public phases, including two companies dual-listed in the U.S. and international markets.

What is Dale A. Sander's net worth?: The estimated net worth of Dale A. Sander is at least $52.78 thousand as of April 10th, 2025. Mr. Sander owns 40,600 shares of Humacyte stock worth more than $52,780 as of December 4th. This net worth approximation does not reflect any other assets that Mr. Sander may own. Additionally, Mr. Sander receives an annual salary of $704,330.00 as CFO at Humacyte. Learn More about Dale A. Sander's net worth.
How old is Dale A. Sander?: Mr. Sander is currently 64 years old. There are 5 older executives and no younger executives at Humacyte. Learn More on Dale A. Sander's age.
What is Dale A. Sander's salary?: As the CFO of Humacyte, Inc., Mr. Sander earns $704,330.00 per year. The highest earning executive at Humacyte is Dr. Laura E. Niklason M.D., Ph.D., Founder, President, CEO & Director, who commands a salary of $899,250.00 per year. Learn More on Dale A. Sander's salary.
How do I contact Dale A. Sander?: The corporate mailing address for Mr. Sander and other Humacyte executives is 1177 AVENUE OF THE AMERICAS 5TH FLOOR, NEW YORK NY, 10036. Humacyte can also be reached via phone at 919-313-9633 and via email at [email protected]. Learn More on Dale A. Sander's contact information.
Has Dale A. Sander been buying or selling shares of Humacyte?: Dale A. Sander has not been actively trading shares of Humacyte within the last three months. Most recently, on Thursday, April 10th, Dale A. Sander bought 20,000 shares of Humacyte stock. The stock was acquired at an average cost of $1.53 per share, with a total value of $30,600.00. Following the completion of the transaction, the chief financial officer now directly owns 40,600 shares of the company's stock, valued at $62,118. Learn More on Dale A. Sander's trading history.
Who are Humacyte's active insiders?: Humacyte's insider roster includes Michael Constantino (Director), Brady Dougan (Director), Laura Niklason (CEO), Shamik Parikh (Chief Medical Officer), Heather Prichard (COO), Dale Sander (CFO), William Scheessele (Chief Commercial Officer), and Kathleen Sebelius (Director). Learn More on Humacyte's active insiders.
Are insiders buying or selling shares of Humacyte?: During the last twelve months, Humacyte insiders bought shares 5 times. They purchased a total of 88,593 shares worth more than $138,418.22. During the last twelve months, insiders at the sold shares 6 times. They sold a total of 4,482,090 shares worth more than $7,466,382.20. The most recent insider tranaction occured on August, 20th when Director Brady W Dougan sold 591,685 shares worth more than $934,862.30. Insiders at Humacyte own 5.1% of the company. Learn More about insider trades at Humacyte.
Information on this page was last updated on 8/20/2025.

Dale A. Sander Insider Trading History at Humacyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/10/2025	Buy	20,000	$1.53	$30,600.00	40,600
8/27/2024	Sell	39,389	$6.68	$263,118.52	2,000
12/16/2022	Buy	20,000	$2.60	$52,000.00	20,600
5/17/2022	Buy	2,000	$4.53	$9,060.00	2,000

Dale A. Sander Buying and Selling Activity at Humacyte

Humacyte Company Overview

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Today's Range

Now: $1.30

$1.26

$1.33

50 Day Range

MA: $1.53

$1.12

$2.48

2 Week Range

Now: $1.30

$1.09

$6.77

Volume

3,077,595 shs

Average Volume

4,793,646 shs

Market Capitalization

$243.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.9

Dale Sander Biography and Net Worth

What is Dale A. Sander's net worth?

How old is Dale A. Sander?

What is Dale A. Sander's salary?

How do I contact Dale A. Sander?

Has Dale A. Sander been buying or selling shares of Humacyte?

Who are Humacyte's active insiders?

Are insiders buying or selling shares of Humacyte?